umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Overall survival (OS) in metastatic renal cell carcinoma (MRCC): a comparison between sorafenib (SO) and best supportive care (BSC)after first line treatment with sunitinib (SU) inSweden
Show others and affiliations
2012 (English)In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 23, no Suppl. 9, 281-281 p.Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
Oxford University Press, 2012. Vol. 23, no Suppl. 9, 281-281 p.
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-61572ISI: 000309409001330OAI: oai:DiVA.org:umu-61572DiVA: diva2:582094
Conference
37th Congress of the European-Society-for-Medical-Oncology (ESMO), SEP 28-OCT 02, 2012, Vienna, AUSTRIA
Available from: 2013-01-03 Created: 2012-11-20 Last updated: 2017-12-06Bibliographically approved

Open Access in DiVA

No full text

Search in DiVA

By author/editor
Ljungberg, Börje
By organisation
Urology and Andrology
In the same journal
Annals of Oncology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 42 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf